How Much Does ESG Cost? Endoscopic Sleeve Gastroplasty Price vs a GLP-1

Endoscopic sleeve gastroplasty (ESG, the “incisionless sleeve” or “accordion procedure”) usually costs roughly $8,000–$20,000 in the United States, and you will almost always pay it out of pocket, because most insurers still classify ESG as investigational and refuse to cover it — the opposite of surgical bariatric procedures, which are frequently covered when medical criteria are met. Those dollar figures are current US market ranges, not numbers from any clinical trial. The number that is from the trials, and the one that justifies the price, is the weight loss: about 13.6% total body weight loss at one year in the randomized MERIT trial^[1], roughly 15–17% pooled^[2], and near 15.9% still holding at five years^[3]. The real financial question is not “is $8,000–$20,000 a lot?” — it is “how does one large one-time payment with no recurring drug bill compare, over several years, with a GLP-1 like Wegovy or Zepbound that may be partly insured but costs money every month indefinitely?” This article does that math honestly.

The honest summary

• ESG typically costs about $8,000–$20,000 in the US, paid out of pocket. That is a current market range, not a trial figure. The spread reflects geography, the endoscopist's experience, the facility, and anesthesia — not different versions of the procedure.
• Insurance usually says no. Most payers still label ESG “investigational” or “experimental” and exclude it, even though they often cover surgical sleeve gastrectomy or gastric bypass. That single classification is the biggest driver of ESG's real-world cost.
• The value case rests on durable, one-time weight loss. ESG produced 13.6% TBWL at a year in the randomized MERIT trial^[1], 15–17% pooled^[2], and 15.9% at five years^[3] — roughly on par with semaglutide^[4], below tirzepatide^[5] and surgery^[6]. You buy that result once.
• A GLP-1 is the recurring-cost alternative. Wegovy or Zepbound can run several hundred to over a thousand dollars a month before insurance, every month, for as long as you take it — and the weight tends to come back if you stop. Over three to five years the cumulative drug spend often exceeds the one-time ESG price.
• Do the multi-year math, not the sticker comparison. A $12,000 procedure looks expensive next to a $0–$500 monthly copay — until you multiply the monthly number by 36 or 60 months. That is the comparison that actually decides value.
• What's in the price matters. A quoted ESG fee should cover the endoscopist, the suturing device, the facility, anesthesia, and follow-up; ask exactly what is bundled before comparing two quotes.
• Financing exists, but read it carefully. Many bariatric-endoscopy programs offer payment plans or medical-credit financing; the convenience can carry meaningful interest, so factor the true total cost, not just the monthly payment.

How much does ESG cost in the US?

In the United States, ESG is typically quoted in the range of about $8,000 to $20,000, with many programs clustering around $10,000–$15,000. This is a current market range gathered from how bariatric-endoscopy programs price the procedure — it is not a trial-derived figure, and no clinical study sets the price. Where a given patient lands within that band depends on a handful of practical factors:

• Geography. Major metro areas and high-cost-of-living regions sit at the upper end; some patients travel domestically or abroad for lower quotes.
• Operator and center. A high-volume bariatric endoscopist at an academic center may charge more than a community program — and experience matters for a suturing procedure, so the cheapest quote is not automatically the best value.
• Facility and anesthesia. ESG is usually an outpatient procedure done in about 60–90 minutes under general anesthesia or deep sedation; the facility fee and anesthesiologist are real line items.
• What's bundled. Some quotes are procedure-only; others fold in the pre-procedure workup, the suturing device, follow-up visits, and the dietitian program. Two “$12,000” quotes can mean very different things.

Why insurance usually won't pay for ESG

This is the crux of ESG's cost problem. Most US insurers still categorize ESG as investigational or experimental and exclude it from coverage — even though the same plans frequently cover surgical sleeve gastrectomy or gastric bypass when a patient meets BMI and comorbidity criteria. The irony is that ESG has a genuine randomized controlled trial behind it (MERIT^[1]) and cleared the medical societies' adoption thresholds, yet payer policy has lagged the evidence. The practical consequences:

• You typically pay the full amount out of pocket. Unlike covered surgery, where you may owe only a deductible and coinsurance, ESG is usually 100% self-pay.
• Coverage is inconsistent and changing. A minority of plans, or specific self-funded employer plans, may cover ESG or reimburse part of it; it is worth requesting your plan's medical policy in writing and asking about an appeal, but do not assume approval.
• The surgery-vs-ESG coverage gap can flip the decision. For some patients, a covered surgical sleeve ends up cheaper out of pocket than a self-pay ESG — even though the surgery is more invasive. That is a real trade-off worth pricing before you choose.

For the surgical side of that comparison, see how much weight-loss surgery costs and whether insurance covers weight-loss surgery.

ESG vs a GLP-1: the multi-year math that actually decides value

Here is the comparison most people are really running: a one-time ESG payment versus an ongoing GLP-1 prescription. The structural difference is everything. ESG is a single large cost with no monthly drug bill afterward; a GLP-1 is a recurring cost every month for as long as you take it — and its weight loss tends to reverse if you stop, so “stopping to save money” often means regaining weight. The dollar figures below are current US market ranges, not trial numbers; the weight-loss percentages are the trial numbers.

Now the arithmetic. Suppose a GLP-1 costs you a net $400 a month after whatever your insurance does (many people pay more; some pay less). That is $4,800 a year, $14,400 over three years, and $24,000 over five years — and it keeps going. A one-time ESG at $12,000 is fully spent by year three in that scenario and cheaper than the drug every year after. If your GLP-1 net cost is higher, or you expect to need weight management for many years, ESG's one-time economics look stronger; if your drug is heavily subsidized (a low copay or a manufacturer program) and you may only need it a year or two, the GLP-1 can be the cheaper path. The honest points:

• The sticker comparison is misleading. $12,000 once vs a few hundred dollars a month only favors the drug if you ignore how many months you will actually take it. Multiply it out over your real time horizon.
• Durability is a cost input, not just an efficacy stat. ESG's weight loss holds near 16% at five years^[3] with no further spend, whereas GLP-1 weight loss depends on continued (paid) dosing. Paying once for a durable result is the core of ESG's value case.
• They are not mutually exclusive, and that changes the budget. Some people use ESG as the durable base and a GLP-1 intermittently, rather than a GLP-1 forever — which can lower lifetime drug spend.
• Efficacy matters too, not just price. If you need tirzepatide-level results (~20.9%^[5]) rather than ESG-range results (~13.6–16%^[1][2]), the drug may simply do more — value is not only about the cheaper option.

Prefer a GLP-1 to a procedure? Top vetted providers

Financing, and how to compare quotes without getting burned

• Payment plans and medical credit. Many bariatric-endoscopy programs partner with medical-financing lenders or offer in-house installment plans. The convenience is real, but so is the interest — a “$300/month” plan can add thousands to the true total. Compare the all-in amount financed, not the monthly payment.
• HSA/FSA dollars. Because ESG is a medical procedure, it is generally payable with pre-tax health-savings or flexible-spending funds, which effectively discounts it by your marginal tax rate. Confirm eligibility with your plan administrator.
• Itemize every quote. Ask each program, in writing, whether the number includes the device, facility, anesthesia, and follow-up. The cheapest headline figure is frequently the least complete.
• Weigh operator experience against price. ESG is a suturing procedure; outcomes and safety track with operator volume. Saving $2,000 by choosing an inexperienced center is a poor trade if it raises your complication risk.
• Price the covered-surgery alternative too. If your insurance would cover a surgical sleeve, get that out-of-pocket estimate as well — sometimes the more invasive but covered option is the cheaper one.

Is ESG worth it? An honest verdict

• ESG is worth it if you want a durable, one-time intervention in the ~13.6–16% weight-loss range^[1][3], you can pay (or finance) $8,000–$20,000 out of pocket, and the multi-year math shows your cumulative GLP-1 cost would exceed that — while you keep up the behavior change that protects the result.
• ESG is probably not the best value if your GLP-1 is heavily subsidized to a low copay, you only expect to need treatment briefly, or you need tirzepatide-level (~20.9%) results^[5] that ESG does not reach.
• A covered surgical sleeve can beat a self-pay ESG on pure out-of-pocket cost for some patients — more invasive, but sometimes cheaper because insurance pays. Always price both.
• The recurring-vs-one-time distinction is the whole game. ESG converts an open-ended monthly liability into a single closed cost; whether that is worth it is a math problem specific to your insurance, your drug, and your time horizon.

Related research

• Endoscopic sleeve gastroplasty (ESG): the full evidence — the cornerstone on efficacy, safety, durability, and how ESG compares to GLP-1s and surgery
• Is ESG reversible? — why the sutures-not-excision design keeps your future surgical options open
• ESG results and before-and-after — what the weight-loss trajectory actually looks like
• ESG vs GLP-1 (semaglutide and tirzepatide) — the focused procedure-vs-drug comparison
• ESG vs gastric sleeve — the incisionless procedure vs the surgical sleeve
• Gastric balloon cost — the other endoscopic option's price picture
• Gastric balloon for weight loss — the temporary 6-month device compared
• Endoscopic weight-loss options: the overview — the pillar map of ESG, the balloon, GLP-1s, and surgery
• How much is weight-loss surgery? — the surgical cost breakdown ESG competes against
• Does insurance cover weight-loss surgery? — why ESG is usually out of pocket while surgery often isn't
• Bariatric surgery vs GLP-1s — the full drugs-vs-surgery weight-loss, cost, and outcomes comparison

Important disclaimer. This article is educational and does not constitute medical or financial advice. Endoscopic sleeve gastroplasty is an invasive procedure with real risks; suitability and pricing depend on your BMI, health, insurance, and the specific program, and must be assessed by a qualified bariatric endoscopist or obesity-medicine physician. Cross-trial comparisons with GLP-1 drugs and with surgery are not head-to-head and should be interpreted with care. All cost figures in this article are current US market ranges, not trial-derived numbers, and actual quotes vary widely by region, operator, and what is bundled. Do not start, stop, or change any treatment based on this article. PMIDs were independently verified against the PubMed E-utilities API on 2026-07-01.

Last verified: 2026-07-01. Next review: every 12 months, or sooner if payer coverage of ESG changes materially or a major long-term ESG cost-effectiveness study is published.